32,663 Shares in Vor Biopharma Inc. $VOR Acquired by Irenic Capital Management LP

Irenic Capital Management LP purchased a new position in Vor Biopharma Inc. (NASDAQ:VOR) in the first quarter, HoldingsChannel.com reports. The firm purchased 32,663 shares of the company’s stock, valued at approximately $583,000.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $36,000. Goldman Sachs Group Inc. grew its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter worth $66,000. Chung Wu Investment Group LLC purchased a new stake in Vor Biopharma during the 4th quarter worth $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma in the 4th quarter worth $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Price Performance

VOR opened at $20.00 on Wednesday. The company has a 50-day moving average of $16.48 and a 200-day moving average of $15.36. Vor Biopharma Inc. has a 1-year low of $6.50 and a 1-year high of $53.00.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. On average, sell-side analysts anticipate that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush raised their price objective on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).